Cyclic adenosine monophosphate‐phosphodiesterase (cAMP‐PDE) in lymphocytes from patients with stage III and IV squamous cell carcinoma of the head and neck

Robert L. Banner, William K. Vaughn, King A. Hagey, W. Joseph Thompson, Evan M. Hersh

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

In vivo skin tests using multiple recall and primary antigens such as dinitrochlorobenzine (DNCB) have established that there is decreased cellular‐mediated immune response in patients with squamous cell carcinomas of the head and neck. In vitro testing of lymphocytes using blastogenic mitogens as a measure of lymphocyte function has not always shown a statistical difference between patients and controls. cAMP‐PDE was assayed in lymphocytes from normal controls ‐ patients with benign conditions in various age groups. No significant difference was found in the specific activity (Vmax) or affinity (Km) in these groups. The mean average was used as a normal control value. In lymphocytes from untreated patients with Stage III and IV squamous cell carcinomas of the head and neck, the Vmax and Km of cAMP‐PDE were higher than the controls. This difference was statistically significant. Postoperative values were also determined but were not statistically different. There were no differences found in blastogenesis in these two groups.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalJournal of Surgical Oncology
Volume9
Issue number1
DOIs
StatePublished - 1977

Keywords

  • affinity
  • anergic
  • blastogenesis
  • cAMP
  • cAMP‐PDE
  • kinetics

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Cyclic adenosine monophosphate‐phosphodiesterase (cAMP‐PDE) in lymphocytes from patients with stage III and IV squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

  • Cite this